Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03413982 · ClinicalTrials.gov registry record
Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers
A clinical trial of Bladder Cancer, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT03413982 is a study of Bladder Cancer that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 1,000 participants, below the 12,748-participant average among 175 other Bladder Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03413982, a study of Bladder Cancer, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments. The registry will be used by researchers to learn more about long term outcome of patients with bladder cancer, how bladder cancer tissues are related to tumor development, recurrence and survival.
Conditions Studied
Interventions
- OTHER Registry
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2017-11-02 |
| Est. Completion | 2035-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03413982
The ClinicalTrials.gov registry entry for NCT03413982 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,748-participant average among 175 other Bladder Cancer trials with a reported enrollment target (92% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Registry is the first listed.
NCT03413982 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT03413982 about?
NCT03413982 is a clinical study titled "Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers". The purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments. The registry will be used by researchers to learn more about long term outcome of patients with bladder cancer, how bladder cancer tissues are re...
What is the current status of trial NCT03413982?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2017-11-02. Estimated completion is 2035-01-01.
What conditions does trial NCT03413982 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT03413982?
The interventions under investigation include: Registry (OTHER).
Who is sponsoring clinical trial NCT03413982?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03413982 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.